An Overview of the Evidence on Environmental and Occupational Determinants of Cancer
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Meat, Fish and Dairy Products and the Risk of Cancer: a Summary Matrix 7 2
Meat, fish and dairy products and the risk of cancer 2018 Contents World Cancer Research Fund Network 3 Executive summary 5 1. Meat, fish and dairy products and the risk of cancer: a summary matrix 7 2. Summary of Panel judgements 9 3. Definitions and patterns 11 3.1 Red meat 11 3.2 Processed meat 12 3.3 Foods containing haem iron 13 3.4 Fish 13 3.5 Cantonese-style salted fish 13 3.6 Grilled (broiled) or barbecued (charbroiled) meat and fish 14 3.7 Dairy products 14 3.8 Diets high in calcium 15 4. Interpretation of the evidence 16 4.1 General 16 4.2 Specific 16 5. Evidence and judgements 27 5.1 Red meat 27 5.2 Processed meat 31 5.3 Foods containing haem iron 35 5.4 Fish 36 5.5 Cantonese-style salted fish 37 5.6 Grilled (broiled) or barbecued (charbroiled) meat and fish 40 5.7 Dairy products 41 5.8 Diets high in calcium 51 5.9 Other 52 6. Comparison with the 2007 Second Expert Report 52 Acknowledgements 53 Abbreviations 57 Glossary 58 References 65 Appendix 1: Criteria for grading evidence for cancer prevention 71 Appendix 2: Mechanisms 74 Our Cancer Prevention Recommendations 79 2 Meat, fish and dairy products and the risk of cancer 2018 WORLD CANCER RESEARCH FUND NETWORK Our Vision We want to live in a world where no one develops a preventable cancer. Our Mission We champion the latest and most authoritative scientific research from around the world on cancer prevention and survival through diet, weight and physical activity, so that we can help people make informed choices to reduce their cancer risk. -
Medical Oncology and Breast Cancer
The Breast Center Smilow Cancer Hospital 20 York Street, North Pavilion New Haven, CT 06510 Phone: (203) 200-2328 Fax: (203) 200-2075 MEDICAL ONCOLOGY Treatment for breast cancer is multidisciplinary. The primary physicians with whom you may meet as part of your care are the medical oncologist, the breast surgeon, and often the radiation oncologist. A list of these specialty physicians will be provided to you. Each provider works with a team of caregivers to ensure that every patient receives high quality, personalized, breast cancer care. The medical oncologist specializes in “systemic therapy”, or medications that treat the whole body. For women with early stage breast cancer, systemic therapy is often recommended to provide the best opportunity to prevent breast cancer from returning. SYSTEMIC THERAPY Depending on the specific characteristics of your cancer, your medical oncologist may prescribe systemic therapy. Systemic therapy can be hormone pills, IV chemotherapy, antibody therapy (also called “immunotherapy”), and oral chemotherapy; sometimes patients receive more than one type of systemic therapy. Systemic therapy can happen before surgery (called “neoadjuvant therapy”) or after surgery (“adjuvant therapy”). If appropriate, your breast surgeon and medical oncologist will discuss the benefits of neoadjuvant and adjuvant therapy with you. As a National Comprehensive Cancer Network (NCCN) Member Institution, we are dedicated to following the treatment guidelines that have been shown to be most effective. We also have a variety of clinical trials that will help us find better ways to treat breast cancer. Your medical oncologist will recommend what treatment types and regimens are best for you. The information used to make these decisions include: the location of the cancer, the size of the cancer, the type of cancer, whether the cancer is invasive, the grade of the cancer (a measure of its aggressiveness), prognostic factors such as hormone receptors and HER2 status, and lymph node involvement. -
Evaluation of the Frequency of Patients with Cancer Presenting to an Emergency Department
ORIGINAL ARTICLE Evaluation of the frequency of patients with cancer presenting to an emergency department Cem Isikber1 Muge Gulen1 Salim Satar2 Akkan Avci1 Selen Acehan1 Gulistan Gul Isikber3 Onder Yesiloglu1 1. Adana City Training and Research Hospital, Department of Emergency Medicine, Adana, Turkey. 2. Associate Professor, Adana City Training and Research Hospital, Department of Emergency Medicine, Adana, Turkey. 3. Adana City Training and Research Hospital, Department of Infectious Diseases and Microbiology, Adana, Turkey. http://dx.doi.org/10.1590/1806-9282.66.10.1402 SUMMARY OBJECTIVE: This study aims to determine the demographic characteristics of cancer patients admitted to an emergency department and determine the relationship between the frequency of admission to the emergency department and oncological emergencies and their effect on mortality. METHODS: This observational, prospective, diagnostic accuracy study was performed in the ED of a tertiary care hospital. Patients over the age of 18 who were previously diagnosed with cancer and admitted to the emergency service for medical reasons were included in the study. We recorded baseline characteristics including age, gender, complaints, oncological diagnosis, metastasis status, cancer treatments received, the number of ED admissions, structural and metabolic oncological emergency diagnoses in the ED, discharge status, length of hospital stay, and mortality status. RESULTS: In our study, 1205 applications related to the oncological diagnosis of 261 patients were examined. 55.6% of the patients were male, and 44.4% were female. The most common metabolic oncological emergency was anemia (19.5%), and the most common structural oncological emergency was bone metastasis-fracture (4.6%.) The mean score of admission of patients to the emergency department was four times (min: 1 max: 29) during the study period. -
Exposure to Carcinogens and Work-Related Cancer: a Review of Assessment Methods
European Agency for Safety and Health at Work ISSN: 1831-9343 Exposure to carcinogens and work-related cancer: A review of assessment methods European Risk Observatory Report Exposure to carcinogens and work-related cancer: A review of assessment measures Authors: Dr Lothar Lißner, Kooperationsstelle Hamburg IFE GmbH Mr Klaus Kuhl (task leader), Kooperationsstelle Hamburg IFE GmbH Dr Timo Kauppinen, Finnish Institute of Occupational Health Ms Sanni Uuksulainen, Finnish Institute of Occupational Health Cross-checker: Professor Ulla B. Vogel from the National Working Environment Research Centre in Denmark Project management: Dr Elke Schneider - European Agency for Safety and Health at Work (EU-OSHA) Europe Direct is a service to help you find answers to your questions about the European Union Freephone number (*): 00 800 6 7 8 9 10 11 (*) Certain mobile telephone operators do not allow access to 00 800 numbers, or these calls may be billed. More information on the European Union is available on the Internet ( 48TU http://europa.euU48T). Cataloguing data can be found on the cover of this publication. Luxembourg: Publications Office of the European Union, 2014 ISBN: 978-92-9240-500-7 doi: 10.2802/33336 Cover pictures: (clockwise): Anthony Jay Villalon (Fotolia); ©Roman Milert (Fotolia); ©Simona Palijanskaite; ©Kari Rissa © European Agency for Safety and Health at Work, 2014 Reproduction is authorised provided the source is acknowledged. European Agency for Safety and Health at Work – EU-OSHA 1 Exposure to carcinogens and work-related cancer: -
About Ovarian Cancer Overview and Types
cancer.org | 1.800.227.2345 About Ovarian Cancer Overview and Types If you have been diagnosed with ovarian cancer or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Is Ovarian Cancer? Research and Statistics See the latest estimates for new cases of ovarian cancer and deaths in the US and what research is currently being done. ● Key Statistics for Ovarian Cancer ● What's New in Ovarian Cancer Research? What Is Ovarian Cancer? Cancer starts when cells in the body begin to grow out of control. Cells in nearly any part of the body can become cancer and can spread. To learn more about how cancers start and spread, see What Is Cancer?1 Ovarian cancers were previously believed to begin only in the ovaries, but recent evidence suggests that many ovarian cancers may actually start in the cells in the far (distal) end of the fallopian tubes. 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 What are the ovaries? Ovaries are reproductive glands found only in females (women). The ovaries produce eggs (ova) for reproduction. The eggs travel from the ovaries through the fallopian tubes into the uterus where the fertilized egg settles in and develops into a fetus. The ovaries are also the main source of the female hormones estrogen and progesterone. One ovary is on each side of the uterus. The ovaries are mainly made up of 3 kinds of cells. Each type of cell can develop into a different type of tumor: ● Epithelial tumors start from the cells that cover the outer surface of the ovary. -
A Study on Tumor Suppressor Genes Mutations Associated with Different Pppathologicalpathological Cccolorectalcolorectal Lllesions.Lesions
A Study on Tumor Suppressor Genes Mutations Associated with Different PPPathologicalPathological CCColorectalColorectal LLLesions.Lesions. Thesis Submitted for partial fulfillment of the requirements for the Ph.D. degree of Science in Biochemistry By Salwa Naeim Abd ElEl----KaderKader Mater M.Sc. in Biochemistry, 2002 Biological Applications Department Nuclear Research Center Atomic Energy Authority Under the supervision of Prof. Dr. Amani F.H Nour El ---Deen Prof. Dr. Abdel Hady Ali Abdel Wahab Professor of Biochemistry Professor of Biochemistry Biochemistry Department and Molecular Biology Faculty of Science Cancer Biology Department Ain Shams University National Cancer Institute Cairo University Prof. DrDr.MohsenMohsen Ismail Mohamed Dr. Azza Salah Helmy Professor of Clinical Pathology Biological Assistant Professor of Biochemistry Applications Department Biochemistry Department Nuclear Research Center Faculty of Science Atomic Energy Authority Ain Shams University 2012011111 ﺑﺴﻢ ﺍﷲ ﺍﻟﺮﺣﻤﻦ ﺍﻟﺮﺣﻴﻢ ﺇِﻧﻤﺎ ﺃﹶﻣﺮﻩ ﺇِﺫﹶﺍ ﺃﹶﺭﺍﺩ ﺷﻴﺌﹰﺎ ﺃﹶﹾﻥ ﻳﹸﻘﻮﻝﹶ ﻟﹶﻪ ﻛﹸـﻦ ﻓﹶﻴﻜﹸـﻮ ﻥ ﹸ ””” ٨٢٨٨٢٢٨٢““““ﻓﹶﺴﺒﺤﺎﻥﹶ ﺍﱠﻟﺬِﻱ ﺑِﻴﺪِﻩِ ﻣﻠﹶﻜﹸﻮﺕ ﻛﹸـﻞﱢ ﺷـﻲﺀٍ ﻭﺇِﻟﹶﻴـﻪِ ﺗﺮﺟﻌﻮﻥﹶ ””” ٨٣٨٨٣٣٨٣““““ ﺻﺪﻕ ﺍﷲ ﺍﻟﻌﻈﻴﻢ رة (٨٢-٨٣) I declare that this thesis has been composed by myself and the work there in has not been submitted for a degree at this or any other university. Salwa Naeim Abd El-Kader Matter To my dear husband and family Their love, encouragement and help made my studies possible and to them I owe everything. Thank you Salwa Naeim Abd El-Kader Matter Acknowledgement First of all, thanks to Allah the most merciful for guiding me and giving me the strength to complete this work. It is pleasure to express my deepest thanks and profound respect to Prof. -
Primary Screening for Breast Cancer with Conventional Mammography: Clinical Summary
Primary Screening for Breast Cancer With Conventional Mammography: Clinical Summary Population Women aged 40 to 49 y Women aged 50 to 74 y Women aged ≥75 y The decision to start screening should be No recommendation. Recommendation Screen every 2 years. an individual one. Grade: I statement Grade: B Grade: C (insufficient evidence) These recommendations apply to asymptomatic women aged ≥40 y who do not have preexisting breast cancer or a previously diagnosed high-risk breast lesion and who are not at high risk for breast cancer because of a known underlying genetic mutation Risk Assessment (such as a BRCA1 or BRCA2 gene mutation or other familial breast cancer syndrome) or a history of chest radiation at a young age. Increasing age is the most important risk factor for most women. Conventional digital mammography has essentially replaced film mammography as the primary method for breast cancer screening Screening Tests in the United States. Conventional digital screening mammography has about the same diagnostic accuracy as film overall, although digital screening seems to have comparatively higher sensitivity but the same or lower specificity in women age <50 y. For women who are at average risk for breast cancer, most of the benefit of mammography results from biennial screening during Starting and ages 50 to 74 y. While screening mammography in women aged 40 to 49 y may reduce the risk for breast cancer death, the Stopping Ages number of deaths averted is smaller than that in older women and the number of false-positive results and unnecessary biopsies is larger. The balance of benefits and harms is likely to improve as women move from their early to late 40s. -
Occupational Cancer Risk Series Diesel Engine Exhaust
Occupational Cancer Risk Series Diesel engine exhaust There may be hazards where you work that increase your risk of developing cancer. This factsheet discusses occupational hazards related to diesel engine exhaust (DEE). Key messages • fuel used (e.g. low-sulphur diesel) • use of emission control system/s • In Australia, it is estimated that 1.2 million workers from many jobs are exposed to diesel • state of engine tuning and maintenance engine exhaust (DEE). • pattern of use (load and acceleration) • DEE contains airborne chemicals that are known • length of time the worker is exposed to cause cancer (carcinogens). Effective controls • Eliminate or reduce exposure to carcinogens by All Australian workplaces must follow work health using recommended controls. and safety laws; however these vary slightly • Refer to Safe Work Australia’s Guidance for between states and territories, but the duty of care Managing the Risks of Diesel Exhaust for more for employers and responsibilities of workers across information or contact your state or territory Australia is similar: work health and safety regulator. • Employers are required to ensure the health and Diesel engine exhaust and cancer safety of their workers at their workplace. DEE is created by burning diesel fuels. It contains a • Employers are required to ensure the health and mixture of airborne chemicals that can be harmful safety other people due to the work carried out. to people. When breathed in, these chemicals • Employers have a duty to control the risks increase your risk of developing long-term health associated with work. problems. This includes lung cancer and possibly bladder cancer. -
Environmental Causes of Cancer
British Toxicology Society http://www.thebts.org/ Environmental Causes of Cancer What is cancer? Cancer is the uncontrolled replication of cells. Such cells have different characteristics from regular cells, enabling them to escape the normal mechanisms controlling cell division and fate. Cancer develops when cells progressively acquire several of these characteristics. Cancer is a major cause of morbidity and mortality throughout the world. During their lifetime, approximately 50% of the population will develop cancer and, globally, almost 17% will die of cancer. Cancer is spoken of as if it were a single disease, but it is a multiplicity of diseases, each with its own aetiology, risk factors and population trends. Nevertheless, amongst adverse health effects, it is amongst those diseases treated with most dread, not surprisingly given that some forms of cancer are untreatable and have a very high mortality rate. Cancer is a progressive and persistent disease and it typically takes approx. 25% of a lifespan to develop cancer in a solid tissue, such as the liver or lung. A corollary of this is that most cancers are diseases of older age, and almost 50% of cancer deaths are in the over 70s. Hence, as the population ages, the proportion dying of cancer increases. This, in part, reflects the effectiveness of improving population longevity. Given the above, there has been intense focus over the last 50 years in trying to identify the causes of cancer, in that prevention would be the most effective public health strategy. Early studies concluded that the majority of cancer was environmental in origin and some inferred that this was because of the presence of chemicals in the environment, whereas in fact it meant that most cancers were not obviously inherited, i.e. -
10 Facts You Should Know About Occupational Carcinogens
10 facts you should know about occupational carcinogens Carcinogens are the “time bombs” of hazardous substances in the workplace. But many substances do not develop their deadly effect until years after expo- sure. It’s a risk for the worker that is often underestimated – and represents an enormous challenge for industrial hygienists. The good news is that occup- ational cancer can be prevented through monitoring and protective measures. © Drägerwerk AG & Co. KGaA 1 10 FACTS ABOUT OCCUPATIONAL CARCINOGENS 1. Cancer is a major health hazard in the workplace. Cancer in the workplace is twice as common as occupational accidents. Every year, 660,000 deaths occur worldwide due to work-related cancer.1 2. Plastic is a deadly threat. 3. Carcinogens are toxic to cells. For many years, vinyl chloride was considered to be safe. This com- Carcinogenic substances are a subgroup of toxic agents, which have pound of carbon, hydrogen and chlorine is a raw material used in the the potential to cause cancer in living tissues. Carcinogen exposure production of PVC. In 1974, seven cases of severe (and very rare) can occur from the inhalation, ingestion, or absorption of many dif- liver cancer were found in individuals who worked at a PVC plant in ferent types of substances in our bodies. Louisville, Kentucky. Five of the afflicted workers, all of whom had Carcinogens may increase the risk of cancer by altering cellular worked with vinyl chloride for 20 years, had already died.2 metabolism or damaging substances such as proteins, ribonucleic It is only because of the efforts of the National Institute for Occup- acids, and especially DNA directly in cells – which interferes with ational Safety and Health (NIOSH) and the energetic probing of a biological processes. -
Hematopoietic and Lymphoid Neoplasm Coding Manual
Hematopoietic and Lymphoid Neoplasm Coding Manual Effective with Cases Diagnosed 1/1/2010 and Forward Published August 2021 Editors: Jennifer Ruhl, MSHCA, RHIT, CCS, CTR, NCI SEER Margaret (Peggy) Adamo, BS, AAS, RHIT, CTR, NCI SEER Lois Dickie, CTR, NCI SEER Serban Negoita, MD, PhD, CTR, NCI SEER Suggested citation: Ruhl J, Adamo M, Dickie L., Negoita, S. (August 2021). Hematopoietic and Lymphoid Neoplasm Coding Manual. National Cancer Institute, Bethesda, MD, 2021. Hematopoietic and Lymphoid Neoplasm Coding Manual 1 In Appreciation NCI SEER gratefully acknowledges the dedicated work of Drs, Charles Platz and Graca Dores since the inception of the Hematopoietic project. They continue to provide support. We deeply appreciate their willingness to serve as advisors for the rules within this manual. The quality of this Hematopoietic project is directly related to their commitment. NCI SEER would also like to acknowledge the following individuals who provided input on the manual and/or the database. Their contributions are greatly appreciated. • Carolyn Callaghan, CTR (SEER Seattle Registry) • Tiffany Janes, CTR (SEER Seattle Registry) We would also like to give a special thanks to the following individuals at Information Management Services, Inc. (IMS) who provide us with document support and web development. • Suzanne Adams, BS, CTR • Ginger Carter, BA • Sean Brennan, BS • Paul Stephenson, BS • Jacob Tomlinson, BS Hematopoietic and Lymphoid Neoplasm Coding Manual 2 Dedication The Hematopoietic and Lymphoid Neoplasm Coding Manual (Heme manual) and the companion Hematopoietic and Lymphoid Neoplasm Database (Heme DB) are dedicated to the hard-working cancer registrars across the world who meticulously identify, abstract, and code cancer data. -
Overview of Occupational Cancer in Painters in Korea Jun-Pyo Myong1,2, Younmo Cho1, Min Choi1 and Hyoung-Ryoul Kim1,2*
Myong et al. Annals of Occupational and Environmental Medicine (2018) 30:10 https://doi.org/10.1186/s40557-018-0222-3 REVIEW Open Access Overview of occupational cancer in painters in Korea Jun-Pyo Myong1,2, Younmo Cho1, Min Choi1 and Hyoung-Ryoul Kim1,2* Abstract Comprehensive consideration is necessary for setting guidelines to evaluate evidence of occupational cancer in painters due to work-related exposure to carcinogens in paint (a phenomenon termed herein as “work-relatedness”). The aim of the present research is to perform a comprehensive review and to suggest criteria for the provision of compensation for occupational neoplasm among painters in Korea. In order to perform a comprehensive review, this study assessed and evaluated scientific reports of carcinogenicities from the International Agency for Research on Cancer (IARC) and the Industrial Injuries Advisory Council (IIAC), as well as reviewed the existing literature about occupational exposure among painters in Korea and the epidemiologic investigations of claimed cases of cancer among painters in Korea. The IARC declares that occupational exposures in commercial painting are classified as Group 1 carcinogens for lung cancer and bladder cancer among painters. The epidemiologic studies show consistent causal relationships between occupational exposure in painters and cancers such as lung cancer [meta relative risk: 1.34 (95% confidence intervals (CIs): 1.23-1.41)] and bladder cancer [meta relative risk: 1.24 (95% CIs: 1.16-1.33)]. In reviewing occupational cancer risks for commercial painters, the Industrial Injuries Advisory Council (IIAC) confirms occupational cancer risks for lung and bladder cancer among commercial painters. According to the IIAC, however, the elevated cancer risks reported in existing literature are not doubled in either lung or bladder cancer in commercial painters relative to the risks of these cancers in the general population.